Engineered CD46-specific effector cells and uses thereof in the treatment of cancer
US12049511B2 · kind B2 · utility
0Cited by
161References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2017 |
| Grant date | Jul 30, 2024 |
| Priority date | — |
| Expiry date | Mar 30, 2039 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2510/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Engineered effector cells, such as chimeric antigen receptors (CARs), are used for enhanced immunogenic response to specific antigen, such as CD46. Disclosed herein are compositions and methods of treatment a cancer overexpressing CD46, which comprises a pharmaceutical composition comprising an engineered effector cell.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.